Roche is rolling out a new diagnostic test to help assess hidden liver fibrosis in patients showing signs of metabolic ...

LONDON, May 07, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced it will present ...

Nature Medicine today published a study showing that Perspectum's iron corrected T1, or cT1, predicts liver-related and cardiac outcomes, including morbidity. Liver disease is a modifiable cardiac ...

Novo Nordisk stock jumped early Wednesday despite cutting its 2025 outlook due to what Novo says is illegal compounding of ...

We recently published a list of Billionaire John Paulson’s 10 Stocks with Huge Upside Potential. In this article, we are ...

An experimental new treatment is showing early promise in the fight against liver fibrosis – a serious and often silent ...

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with ...

A promising target for rare liver cancer, a functional cure for multiple myeloma — and support for people with ovarian cancer.